Overview

Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

HonorHealth Research Institute

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Hydroxychloroquine
Paclitaxel